Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study (Q43134067)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 January 2013

Language	Label	Description	Also known as
English	Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study	scientific article published on 28 January 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study (English)

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Gerhard Ehninger

14

object named as

G Ehninger

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Martin Bornhäuser

9

object named as

M Bornhäuser

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Uwe Platzbecker

1

object named as

U Platzbecker

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

author name string

F Braulke

2

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

A Kündgen

3

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

K Götze

4

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

G Bug

5

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

C Schönefeldt

6

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

K Shirneshan

7

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

C Röllig

8

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

R Naumann

10

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

J Neesen

11

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

A Giagounidis

12

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

W-K Hofmann

13

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

U Germing

15

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

D Haase

16

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

M Wermke

17

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

publication date

28 January 2013

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

27

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

1403-1407

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Clinical effect of point mutations in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

25 May 2018

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

15 August 2018

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

15 August 2018

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3677141

15 August 2018

PET scans: when and how?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.26

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.26

21 January 2018

Identifiers

10.1038/LEU.2013.26

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43134067&oldid=2205815651"